Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D0T5OF
|
|||
| Drug Name |
PMID28270010-Compound-Figure17-2
|
|||
| Drug Type |
Small molecular drug
|
|||
| Company |
ARRAY BIOPHARMA INC
|
|||
| Structure |
 |
Download2D MOL |
||
| Formula |
C29H31F2N7O2
|
|||
| Canonical SMILES |
CC1=C(N(N=C1C2=CN=C(N=C2)C)C3=CC=CC=C3)NC(=O)NC4CN(CC4C5=CC(=C(C=C5)F)F)CCOC
|
|||
| InChI |
1S/C29H31F2N7O2/c1-18-27(21-14-32-19(2)33-15-21)36-38(22-7-5-4-6-8-22)28(18)35-29(39)34-26-17-37(11-12-40-3)16-23(26)20-9-10-24(30)25(31)13-20/h4-10,13-15,23,26H,11-12,16-17H2,1-3H3,(H2,34,35,39)/t23-,26+/m0/s1
|
|||
| InChIKey |
HMZMJVUIFWVPPL-JYFHCDHNSA-N
|
|||
| PubChem Compound ID | ||||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Tropomyosin-related kinase A (TrkA) | Target Info | Inhibitor | [1] |
| Target's Patent Info | Tropomyosin-related kinase A (TrkA) | Target's Patent Info | [1] | |
| KEGG Pathway | MAPK signaling pathway | |||
| Endocytosis | ||||
| Apoptosis | ||||
| Neurotrophin signaling pathway | ||||
| Inflammatory mediator regulation of TRP channels | ||||
| Pathways in cancer | ||||
| Transcriptional misregulation in cancer | ||||
| Thyroid cancer | ||||
| Central carbon metabolism in cancer | ||||
| NetPath Pathway | IL2 Signaling Pathway | |||
| Pathway Interaction Database | Neurotrophic factor-mediated Trk receptor signaling | |||
| Reactome | Frs2-mediated activation | |||
| ARMS-mediated activation | ||||
| NGF-independant TRKA activation | ||||
| PI3K/AKT activation | ||||
| WikiPathways | MAPK Signaling Pathway | |||
| BDNF signaling pathway | ||||
| Integrated Pancreatic Cancer Pathway | ||||
| NGF signalling via TRKA from the plasma membrane | ||||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | Tropomyosin receptor kinase inhibitors: an updated patent review for 2010-2016 - Part I.Expert Opin Ther Pat. 2017 Jun;27(6):733-751. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.